CollPlant Biotechnologies (NASDAQ:CLGN) Earns “Buy” Rating from HC Wainwright

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $11.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 158.91% from the company’s previous close.

CLGN has been the topic of several other research reports. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a research note on Monday, August 5th. D. Boral Capital reiterated a “buy” rating and set a $14.00 target price on shares of CollPlant Biotechnologies in a research note on Wednesday.

CollPlant Biotechnologies Stock Down 0.4 %

Shares of NASDAQ:CLGN traded down $0.02 during trading on Friday, hitting $4.25. The stock had a trading volume of 21,051 shares, compared to its average volume of 18,116. CollPlant Biotechnologies has a 12 month low of $3.31 and a 12 month high of $6.99. The company has a market capitalization of $48.65 million, a PE ratio of -2.76 and a beta of 0.44. The firm’s fifty day moving average is $4.30 and its 200 day moving average is $4.85.

Hedge Funds Weigh In On CollPlant Biotechnologies

A number of institutional investors and hedge funds have recently modified their holdings of the company. Benjamin Edwards Inc. purchased a new position in shares of CollPlant Biotechnologies in the 3rd quarter worth $112,000. Villere ST Denis J & Co. LLC raised its holdings in CollPlant Biotechnologies by 24.4% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after purchasing an additional 95,000 shares during the period. Finally, Pinnacle Associates Ltd. raised its holdings in CollPlant Biotechnologies by 6.4% in the 2nd quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after purchasing an additional 33,905 shares during the period. 21.69% of the stock is currently owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.